Export 5 results:
Autore Titolo [ Tipo(Desc)] Anno
Filtri: Autore è Bosco, Raffaella  [Clear All Filters]
Journal Article
Bosco R, Rabusin M, Voltan R, Celeghini C, Corallini F, Capitani S, Secchiero P. Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells. Invest New Drugs 2012;30(1):417-22.
Zauli G, Voltan R, Bosco R, Melloni E, Marmiroli S, Rigolin GMatteo, Cuneo A, Secchiero P. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. Clin Cancer Res 2011;17(4):762-70.
Zauli G, Voltan R, di Iasio MGrazia, Bosco R, Melloni E, Sana MElena, Secchiero P. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res 2011;17(9):2712-24.
Zauli G, Bosco R, Secchiero P. Molecular targets for selective killing of TRAIL-resistant leukemic cells. Expert Opin Ther Targets 2011;15(8):931-42.
Secchiero P, Bosco R, Celeghini C, Zauli G. Recent advances in the therapeutic perspectives of Nutlin-3. Curr Pharm Des 2011;17(6):569-77.

Amministrazione Trasparente